ArticlePhysical and engineering sciences in medicine2025
Explainable hierarchical machine-learning approaches for multimodal prediction of conversion from mild cognitive impairment to Alzheimer's disease.
Article in Physical and engineering sciences in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical pathways matter for multimodal deep learning in early Alzheimer's disease detection.Scientific reports · 2026Article
- Explainable Machine Learning Reveals Time-Dependent Cognitive Risk in Minor Neurocognitive Disorder: Implications for Health Promotion and Early Risk Stratification.Biomedicines · 2026Article
- Interpretable machine learning to predict NOAF in ICU patients with CKD: validation in US and Chinese cohorts.Frontiers in medicine · 2026Article
- Detecting Mild Cognitive Impairment to Alzheimer's Disease Progression by fMRI Using Convolutional Neural Network and Long-short Term Memory.Basic and clinical neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that challenges early diagnosis and intervention, yet the black-box nature of many predictive models limits clinical adoption. In this study, we developed an advanced machine learning (ML) framework that integrates hierarchical feature selection with multiple classifiers to predict progression from mild cognitive impairment (MCI) to AD. Using baseline data from 580 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI), categorized into stable MCI (sMCI) and progressive MCI (pMCI) subgroups, we analyzed features both individually and across seven key groups. The neuropsychological test group exhibited the highest predictive power, with several of the top individual predictors drawn from this domain. Hierarchical feature selection combining initial statistical filtering and machine learning based refinement, narrowed the feature set to the eight most informative variables. To demystify model decisions, we applied SHAP-based (SHapley Additive exPlanations) explainability analysis, quantifying each feature's contribution to conversion risk. The explainable random forest classifier, optimized on these selected features, achieved 83.79% accuracy (84.93% sensitivity, 83.32% specificity), outperforming other methods and revealing hippocampal volume, delayed memory recall (LDELTOTAL), and Functional Activities Questionnaire (FAQ) scores as the top drivers of conversion. These results underscore the effectiveness of combining diverse data sources with advanced ML models, and demonstrate that transparent, SHAP-driven insights align with known AD biomarkers, transforming our model from a predictive black box into a clinically actionable tool for early diagnosis and patient stratification.
Indexed as
Identifiers
40788534What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.